Hepatitis C, Chagas, and dengue research panels, 8/14
August 2014—SeraCare Life Sciences released four research panels that deliver hard-to-find material for hepatitis C, Chagas, and dengue.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
High-sensitivity cTnI antibody pair, 8/14
August 2014—Meridian Life Science is offering a cardiac Troponin-I antibody pair for the development of highly sensitive and specific cTnl sandwich immunoassays. Both capture antibody and detection antibody vials contain 0.2 mg and store at 2°–8°C.
Biological stabilizers for molecular controls, 8/14
August 2014—Microbiologics has partnered with Biomatrica to license Biomatrica’s DNAstable and RNAstable technology for use in its line of molecular controls for rapid diagnostic instruments and assays.
Nuclea, CRL to offer diagnostic assays, 8/14
August 2014—Nuclea Biotechnologies has partnered with Clinical Reference Laboratory for initial CLIA assay validation and subsequent laboratory processing in support of three of Nuclea’s key tests. Initial efforts will focus on Nuclea’s flagship assay, the Oncogene Science 159 gene-based prostate cancer monitoring test, and its Nuvera breast cancer assay.
Bio-Rad extends contract, 8/14
August 2014—Bio-Rad Laboratories has extended its contract with Premier, a U.S.-based group purchasing organization. The agreement includes Premier general level and ASCEND members.
Proteinase–3 (cANCA) native autoantigen, 8/14
August 2014—A Proteinase–3 (cANCA) native autoantigen for the in vitro diagnostics market is available from The Binding Site. Expressly designed for use as an integral component in solid-phase, ELISA-based immunoassay test procedures, the Proteinase–3 (cANCA) native autoantigen is for clinical and life-science researchers, medical laboratory professionals, and manufacturers of in vitro diagnostic immunoassay kits and tests for autoimmune conditions.
Expanded RUO capabilities for MALDI Biotyper, 8/14
August 2014—MALDI Biotyper systems can be configured for further functionality by adding new or expanded research-use only software modules or hardware accessories.
The MBT Explorer module provides multiple bioinformatics approaches for spectra comparison, statistical data interpretation, and the generation of customer-specific reference library entries (main spectra) of strains of special interest. Such sub-libraries can be exported and re-imported in networks of collaborating labs.
Calprotectin assay, 8/14
August 2014—Inova Diagnostics announced the global launch of Quanta Lite Calprotectin, an FDA-cleared, quantitative ELISA that detects calprotectin levels, aids in the diagnosis of inflammatory bowel disease, and can also help differentiate, in conjunction with other laboratory and clinical findings, IBD from irritable bowel syndrome.
Calreticulin biomarker, 8/14
August 2014—Qiagen acquired an exclusive worldwide license to the biomarker calreticulin. Qiagen licensed the technology from CeMM Vienna, the research center for molecular medicine of the Austrian Academy of Sciences. Qiagen plans to develop a molecular diagnostic test for the CALR mutations to offer patients a clearer prognostic profile and to guide disease management.
Xifin forms medical advisory board, 8/14
July 2014—Xifin, the financial cloud computing company for diagnostic service providers, formed a medical advisory board that will share its extensive expertise in pathology operations and workflow, lab automation, regulatory requirements, clinician needs, and pathology informatics important to the company’s product development and strategic initiatives.